Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Alimera Sciences Inc. (NASDAQ:ALIM) jumped $1.63 (71%) to $3.94 on Tuesday, while partner pSivida Corp. (NASDAQ:PSDV; ASX:PVA) gained $0.27 (13%) to $2.42, after the U.K. and six other EU member states reached an agreement in favor of approval of Iluvien to treat chronic diabetic macular edema. Alimera was up $2.07 (121%) to $3.78 last week while pSivida gained $0.21 (12%) to $1.95. In Australia, pSivida gained A$0.85 (74%) to A$2.
Affymax Inc. (NASDAQ:AFFY) was up $0.27 to $10.65 last week after EMA accepted for review an MAA from partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for peginesatide to treat anemia in chronic kidney disease (CKD) patients on dialysis. The acceptance triggered a $5 million milestone payment to Affymax.